AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation

18th May 2020 Uncategorised 0

The drug is being developed for metastatic non-small cell lung cancer (NSCLC) in patients whose tumours have an HER2 mutation and with disease progression on or after platinum-based therapy

More: AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation
Source: News